# VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults

> **NCT03327727** · PHASE2 · TERMINATED · sponsor: **Vical** · enrollment: 4 (actual)

## Conditions studied

- Invasive Aspergillosis
- Invasive Pulmonary Aspergillosis

## Interventions

- **DRUG:** Investigational Agent: VL-2397
- **DRUG:** Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B

## Key facts

- **NCT ID:** NCT03327727
- **Lead sponsor:** Vical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-20
- **Primary completion:** 2019-01-14
- **Final completion:** 2019-01-14
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Business decision
- **Last updated:** 2019-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03327727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03327727, "VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03327727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*